Health-care Professionals’ Knowledge and Perception of Adverse Drug Reaction Reporting and Pharmacovigilance in a Tertiary Care Teaching Hospital of Nepal
Restricted accessResearch articleFirst published online June, 2021
Health-care Professionals’ Knowledge and Perception of Adverse Drug Reaction Reporting and Pharmacovigilance in a Tertiary Care Teaching Hospital of Nepal
Background: Underreporting of adverse drug reactions (ADRs) is common globally, and Nepal is not an exception to this. Health-care professionals (HCPs) play a vital role in reporting ADR during routine practice. Lack of knowledge and awareness about pharmacovigilance and reporting ADRs among HCPs may contribute to underreporting. Objective: The objective of this study was to evaluate the knowledge and perception of HCPs regarding ADR reporting and pharmacovigilance in a tertiary care teaching hospital in, Nepal. Methods: A descriptive cross-sectional study was conducted. A questionnaire was distributed to 215 HCPs (medical doctors, nurses, and pharmacists) between March and September 2018. Knowledge and perception regarding ADR reporting and pharmacovigilance were studied. Data were analyzed using IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp, Armonk, New York). Results: The HCPs included 75 medical doctors, 126 nurses, and 14 pharmacists. Majority of the participants were female (67%), and the majority of participants were not aware of pharmacovigilance. Among the participants, pharmacists were found to have better knowledge regarding pharmacovigilance. However, other HCPs (doctors and nurses) strongly agreed about the necessity of having adequate knowledge about pharmacovigilance. Out of 215, 57.7% agreed that the important benefit of reporting ADR was to identify safe drugs and improve patient safety. The main reasons for not reporting were – ADR reporting was not widely promoted by relevant authorities (47%), followed by not knowing where and how to report ADR (34.9%). However, other HCPs (doctors and nurses) strongly agreed about the necessity of having adequate knowledge about pharmacovigilance. Conclusions: The knowledge of HCPs on ADR reporting and pharmacovigilance was poor. Despite a low knowledge of ADR reporting and pharmacovigilance among HCPs, there was a positive perception that ADR reporting is necessary and ADR monitoring system should be established in the hospital. This study also highlights a need for future intervention studies focusing on educating HCPs about ADR and pharmacovigilance.
BuajordetIEbbesenJErikssenJBrorsOHilbergT.Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001;250(4):327-341.
4.
DaviesECGreenCFTaylorSWilliamsonPRMottramDRPirmohamedM.Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4(2):e4439.
5.
EbbesenJBuajordetIErikssenJ, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001;161(19):2317-2323.
6.
PirmohamedMJamesSMeakinS, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-19.
7.
SaidASAHussainN.Adverse drug reaction reporting practices among United Arab Emirates pharmacists and prescribers. Hosp Pharm. 2017;52(5):361-366.
8.
KhatiwodaSRDhunganaRRSapkotaVPSinghS.Estimating the direct cost of cancer in Nepal: a cross-sectional study in a tertiary cancer hospital. Front Public Health. 2019;7:160.
9.
SweKTRahmanMMRahmanMS, et al. Cost and economic burden of illness over 15 years in Nepal: a comparative analysis. PLoS ONE. 2018;13(4):e0194564.
10.
FaichGA.Adverse-drug-reaction monitoring. N Engl J Med. 1986;314(24):1589-1592.
ShresthaSShresthaSKhanalS.Establishment of the first cancer hospital-based pharmacovigilance center in Nepal. Res Social Adm Pharm. 2018;14(11):1088-1089.
14.
GurungRSShresthaDThapaR.Assessment on knowledge, attitude and practice of pharmacovigilance among the healthcare professionals in a tertiary hospital of Kathmandu. Nepal Med Coll J. 2019;21(1). https://www.nepjol.info/index.php/nmcj/article/view/24854. Accessed October 8, 2019.
15.
JhaNRathoreDSShankarPR, et al. Strengthening adverse drug reaction reporting in Nepal. Asian J Med Sci. 2015;6(4):9-13.
16.
RauniarGPandayD.Adverse drug reaction (ADR) monitoring at the Eastern regional pharmacovigilance centre, Nepal. Kathmandu Univ Med J. 2017;15(60):296-300.
17.
PreetKMalhotraSShrivastavaP, et al. Genetic diversity in Gorkhas: an autosomal STR Study. Sci Rep. 2016;6:32494.
18.
DaarASSingerPA.Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet. 2005;6(3):241-246.
19.
DattaSSenguptaS.An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting in a tertiary care teaching hospital of Sikkim. Perspect Clin Res. 2015;6(4):200-206.
20.
HazellLShakirSA.Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-396.
21.
RabburRSMEmmertonL.An introduction to adverse drug reaction reporting systems in different countries. Int J Pharm Pract. 2005;13(1):91-100.
22.
van GrootheestACde Jong-van den BergLT.The role of hospital and community pharmacists in pharmacovigilance. Res Social Adm Pharm. 2005;1(1):126-133.
23.
van GrootheestKOlssonSCouperMde Jong-van den BergL. Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004;13(7):457-464.
24.
VallanoACerezaGPedròsC, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005;60(6):653-658.
25.
Alvarez-RequejoACarvajalABegaudBMorideYVegaTAriasLH.Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(6):483-488.
26.
HadiMANeohCFZinRMElrggalMECheemaE.Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract. 2017;6:91-98.
27.
ShamimSSharibSMMalhiSM, et al. Adverse drug reactions (ADRS) reporting: awareness and reasons of under-reporting among health care professionals, a challenge for pharmacists. SpringerPlus. 2016;5(1):1778-1778.
28.
AndersonCKrskaJMurphyEAveryA, Yellow Card Study Collaboration. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol. 2011;72(5):806-822.
29.
KhanSARaoPGRodriguesGSRajanSHedaA.From thalidomide to rofecoxib: can we afford to wait and watch?Int J Risk Saf Med. 2006;18(4):219-230.
30.
McBrideWG.Thalidomide and congenital abnormalities. Lancet. 1961;2(1358):90927-90928.
31.
RameshMPanditJParthasarathiG.Adverse drug reactions in a south Indian hospital—Their severity and cost involved. Pharmacoepidemiol Drug Saf. 2003;12(8):687-692.
32.
ShresthaSShresthaSPalaianS.Can clinical pharmacists bridge a gap between medical oncologists and patients in resource-limited oncology settings? an experience in Nepal. J Oncol Pharm Pract. 2019;25(3):765-768.
33.
ShresthaSShresthaSKhanalS.Polypharmacy in elderly cancer patients: challenges and the way clinical pharmacists can contribute in resource-limited settings. Aging Med. 2019;2(1):42-49.
34.
Abdel-LatifMMMAbdel-WahabBA.Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Saudi Pharm J. 2015;23(2):154-161.
35.
AlmandilNB.Healthcare professionals’ awareness and knowledge of adverse drug reactions and pharmacovigilance. Saudi Med J. 2016;37(12):1359-1364.
36.
GurmesaLTDedefoMG.Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia. Biomed Res Int. 2016;2016:5728462.
37.
Abu HammourKEl-DahiyatFAbu FarhaR. Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan. J Eval Clin Pract. 2017;23(3):608-613.
38.
ChhabraKGSharmaAChhabraCReddyJJDeoliaSGMittalY.Knowledge, attitude, and practices regarding pharmacovigilance and adverse drug reaction reporting among dental students in a teaching hospital, Jodhpur, India: a cross-sectional study. J Contemp Dent Pract. 2017;18(10):964-969.
39.
GünerMDEkmekciPE.Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. J Drug Assess. 2019;8(1):13-20.
40.
OreagbaIAOgunleyeOJOlayemiSO.The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, south west Nigeria. Pharmacoepidemiol Drug Saf. 2011;20(1):30-35.
41.
SantoshKCTragulpiankitPGorsananSEdwardsIR.Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal. BMC Pharmacol Toxicol. 2013;14(1):16.
42.
PalaianSIbrahimMIMishraP.Health professionals’ knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharm Pract (Granada). 2011;9(4):228-235.
43.
ShankoHAbdelaJ.Knowledge, attitudes, and practices of health care professionals toward adverse drug reaction reporting in Hiwot Fana Specialized University Hospital, Harar, Eastern Ethiopia: a cross-sectional study. Hosp Pharm. 2018;53(3):177-187.
44.
IffatWShakeelSRahimNAnjumFNesarSGhayasS.Pakistani physicians’ knowledge and attitude towards reporting adverse drug reactions. Afr J Pharm Pharmacol. 2014;8(14):379-385.
45.
ShankarPRSubishPMishraPDubeyA.Teaching pharmacovigilance to medical students and doctors. Indian J Pharmacol. 2006;38(5):316-319.
46.
LiQZhangSMChenHT, et al. Awareness and attitudes of healthcare professionals in Wuhan, China to the reporting of adverse drug reactions. Chin Med J (Engl). 2004;117(6):856-861.
47.
OkezieEOOlufunmilayoF.Adverse drug reactions reporting by physicians in Ibadan, Nigeria. Pharmacoepidemiol Drug Saf. 2008;17(5):517-522.
48.
SuyaghMFarahDAbu FarhaR.Pharmacist’s knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharm J. 2015;23(2):147-153.
49.
HazellLCorneliusVHannafordPShakirSAveryAJ.How do patients contribute to signal detection? a retrospective analysis of spontaneous reporting of adverse drug reactions in the UK’s Yellow Card Scheme. Drug Saf. 2013;36(3):199-206.
50.
VessalGMardaniZMollaiM.Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran. Pharm World Sci. 2009;31(2):183-187.
51.
GuptaSKNayakRPShivaranjaniRVidyarthiSK.A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspect Clin Res. 2015;6(1):45-52.
52.
DesaiCKIyerGPanchalJShahSDikshitRK.An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res. 2011;2(4):129-136.
